98%
921
2 minutes
20
Objective: Cryopyrin-associated periodic syndrome (CAPS) is an autoinflammatory disease caused by gain-of-function mutations in NLRP3. Although somatic NLRP3 mosaicism is increasingly recognized, it remains unclear how variant allele frequency (VAF) changes over time and whether disease onset age reflects differences in somatic mutation dynamics. This study aimed to analyze the longitudinal VAF trends and their correlation with clonal hematopoiesis (CH) in patients with CAPS mosaicism.
Methods: We analyzed NLRP3 VAF in blood and various tissues, including dried umbilical cord (DUC) using digital PCR and deep amplicon sequencing. Whole-exome and single-cell genome sequencing were performed to evaluate CH-related mutations.
Results: We included 15 patients with VAFs of 4.3% to 34.9%. In the 12 early-onset cases, VAFs were generally consistent across various tissues and did not increase over time, including the DUC. Conversely, in the three late-onset cases, VAFs were particularly high in myeloid cells. Notably, in one late-onset case, no mutations were detected in DUC. After disease onset, VAFs exhibited 2.9%-to-10.6% and 6.2%-to-16.4% increase in the whole blood and neutrophils over 6.4 and 4.4 years, respectively, showing a clonal expansion of NLRP3-mutant cells. Single-cell genome sequencing revealed frequent co-occurrence of NLRP3 and TET2 mutations in the same cells, with a gradual increase in both VAFs over 3 years, in one late-onset case.
Conclusion: In early-onset cases, the VAFs were comparable across various tissues and did not increase over time. Mutations in late-onset cases were enriched in myeloid cells, and VAFs were increased, suggesting a link to CH.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/art.43329 | DOI Listing |
Int J Hematol
September 2025
MLL Munich Leukemia Laboratory, Max-Lebsche-Platz 31, 81377, Munich, Germany.
Chronic myeloid leukemia (CML) and BCR::ABL1-negative MPN were thought to be mutually exclusive, but synchronous and sequential cases have been reported. We screened 35,001 patients for BCR::ABL1 fusion or JAK2, CALR, or MPL mutations to investigate the sequential development of CML and BCR::ABL1 negative-MPNs. We discovered that 5.
View Article and Find Full Text PDFVirchows Arch
August 2025
Hematopathology Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
TP53 mutation is a significant negative prognostic factor in mantle cell lymphoma (MCL). While p53 immunohistochemical (IHC) staining is frequently used to evaluate TP53 mutation status, specific cut-offs correlating with mutations remain undefined and largely empirical. This study analyzed tumor specimens from 172 patients with MCL with both p53 IHC and TP53 mutation data, categorizing p53 nuclear expression into four groups (0 + , 1 + , 2 + , and 3 +) using digital image analysis.
View Article and Find Full Text PDFJ Clin Med
July 2025
Department of Pathology and Laboratory Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Greenvale, NY 11548, USA.
Genetic alterations in , typically associated with chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML), rarely occur in other myeloid neoplasms. This study characterized the clinical, morphologic, cytogenetic, and molecular features of 13 patients with non-CNL non-aCML myeloid neoplasms with alterations. Patients (median age, 77 years) were categorized into groups with a myelodysplastic/myeloproliferative neoplasm (MDS/MPN) (n = 5), acute leukemia (n = 4), and other myeloid neoplasms (n = 4) based on the WHO 2022 and ICC criteria.
View Article and Find Full Text PDFJ Liq Biopsy
September 2025
Foundation Medicine, Inc., Boston, MA, USA.
Purpose: Genomic profiling of tumors by liquid biopsy (LBx) is a pragmatic alternative to profiling tissue. Despite recent methodologic advances, clonal hematopoiesis (CH) variants arising from hematopoietic stem cells may confound LBx results. Distinguishing the origin of variants detected by LBx will greatly enhance treatment decision-making for patients with cancer.
View Article and Find Full Text PDFBr J Haematol
July 2025
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
The JAK2V617F mutation is associated with increased cardiovascular risk, including ischaemic stroke. This study investigates the prevalence of additional mutations in ischaemic cerebrovascular patients with and without JAK2V617F to better understand the mechanisms contributing to thrombotic risk. We examined 63 patients with the JAK2V617F mutation and 126 matched controls from a cohort of 591 ischaemic cerebrovascular patients.
View Article and Find Full Text PDF